张晓辉 , 孙强 . 年轻乳腺癌高危易患人群的处理策略[J]. 中华乳腺病杂志(电子版), 2014 , 08(03) : 161 -164 . DOI: 10.3877/cma. j. issn.1674-0807.2014.03.002

[1]	Desantis C, Ma J, Bryan L, et al. Breast cancer statistics,2013[EB/OL]. [2014-02-10]. http: / /www. cancer. org/research/cancerfactsstatistics/breast-cancer-facts-figures.

[2]	Partridge AH, Pagani O, Abulkhair O, et al. First international consensus guidelines for breast cancer in young women (BCY1)[J]. Breast,2014,23(3): 209-220.

[3]	Anders CK, Johnson R, Litton J, et al. Breast cancer before age 40 years[J]. Semin Oncol,2009,36(3): 237-249.

[4]	Assi HA, Khoury KE, Dbouk H, et al. Epidemiology and prognosis of breast cancer in young women[J]. J Thorac Dis,2013,5(Suppl 1): S2-8.

[5]	Collaborative Group on Hormonal Factors in Breast Cancer.Menarche, menopause, and breast cancer risk: individual participant meta-analysis,including 118 964 women with breast cancer from 117 epidemiological studies [J]. Lancet Oncol,2012,13(11): 1141-1151.

[6]	Peto J, Mack TM. High constant incidence in twins and other relatives of women with breast cancer[J]. Nat Genet, 2000,26 (4): 411-414.

[7]	Lalloo F, Evans DG. Familial breast cancer [J]. Clin Genet,2012,82(2): 105-114.

[8]	Ready K, Litton JK, Arun BK. Clinical application of breast cancer risk assessment models[J]. Future Oncol,2010,6(3): 355-365.

[9]

Fischer C, Kuchenbäcker K, Engel C, et al. Evaluating the performance of the breast cancer genetic risk models BOADICEA, IBIS, BRCAPRO and Claus for predicting BRCA1/2 mutation carrier probabilities: a study based on 7352 families from the German Hereditary Breast and Ovarian Cancer Consortium[J]. J Med Genet,2013,50(6): 360-367.

[10]	National Comprehensive Cancer Network. Genetic/familial high-risk assessment: breast and ovarian,v.4.2013[EB/OL].[2013-12-20]. http: / /www.nccn.org/professionals/physician_gls/pdf/genetics_screening.pdf.

[11]	Warner E, Foulkes W, Goodwin P, et al. Prevalence and penetrance of BRCA1 and BRCA2 gene mutations in unselected Ashkenazi Jewish women with breast cancer[J]. J Natl Cancer Inst,1999,91(14): 1241-1247.

[12]	Riley BD, Culver JO, Skrzynia C, et al. Essential elements of genetic cancer risk assessment, counseling, and testing: updated recommendations of the National Society of Genetic Counselors [J]. J Genet Couns,2012,21(2): 151-161.

[13]

Lee CH, Dershaw DD, Kopans D, et al. Breast cancer screening with imaging: recommendations from the Society of Breast Imaging and the ACR on the use of mammography,breast MRI, breast ultrasound, and other technologies for the detection of clinically occult breast cancer [J]. J Am Coll Radiol,2010,7(1): 18-27.

[14]	American College of Radiology. ACR practice guidelines for the performance of screening and diagnostic mammography, revised 2013[EB/OL]. [2013-08-09]. http: / /www.acr.org / ～/media/ACR/Documents/PGTS/guidelines/Screening _ Mammography.pdf.

[15]	Weigert J,Steenbergen S. The connecticut experiment: the role of ultrasound in the screening of women with dense breasts[J].Breast J,2012,18(6): 517-522.

[16]	沈松杰,孙强,徐雅莉,等. 乳腺癌常用早期诊断方法的比较研究[J].中华肿瘤杂志,2012,34(11),877-880.

[17]	American College of Radiology. ACR practice guideline for performing and interpreting magnetic resonance imaging(MRI), revised 2013[EB/OL]. [2013-08-09]. http: / /www. acr. org/ ～ /media/ACR/Documents/PGTS/guidelines/MRI.pdf.

[18]	National Comprehensive Cancer Network. Clinical practice guidelines in oncology: breast cancer screening and diagnosis.v.2.2013[EB/OL]. [2013-12-20]. http: / /www. nccn. org/professionals/physician_gls/pdf/breast-screening.pdf.

[19]	Steward WP, Brown K. Cancer chemoprevention: a rapidly evolving field [J]. Br J Cancer,2013,109(1): 1-7.

[20]	Nazarali SA, Narod SA. Tamoxifen for women at high risk of breast cancer[J]. Breast Cancer,2014,6: 29-36.

[21]	Goss PE, Ingle JN, Alés-Martínez JE, et al. Exemestane for breast-cancer prevention in postmenopausal women[J]. N Engl J Med,2011,364(25): 2381-2391.

[22]	Cuzick J,Sestak I,Forbes JF,et al. Anastrozole for prevention of breast cancer in high-risk postmenopausal women (IBIS-Ⅱ): an international, double-blind, randomised placebocontrolled trial[J]. Lancet,2014,383(9922): 1041-1048.

[23]	Fagerlin A,Dillard AJ,Smith DM,et al. Women’s interest in taking tamoxifen and raloxifene for breast cancer prevention: response to a tailored decision aid[J]. Breast Cancer Res Treat,2011,127(3): 681-688.

[24]	McLaughlin CC, Lillquist PP, Edge SB. Surveillance of prophylactic mastectomy: trends in use from 1995 through 2005[J]. Cancer,2009,115(23): 5404-5412.

[25]	Soran A,Kamali Polat A,Johnson R,et al. Increasing trend of contralateral prophylactic mastectomy: What are the factors behind this phenomenon?[J]. Surgeon,2014,doi: 10.1016/j.surge.2014.02.005.

[26]

Heemskerk-Gerritsen BA, Menke-Pluijmers MB, Jager A, et al. Substantial breast cancer risk reduction and potential survival benefit after bilateral mastectomy when compared with surveillance in healthy BRCA1 and BRCA2 mutation carriers: a prospective analysis [ J]. Ann Oncol, 2013, 24 (8 ): 2029-2035.

[27]	Pilgrim S, Pain S. Bilateral risk-reducing mastectomy is the safest strategy in BRCA1 carriers[J]. Eur J Surg Oncol,2014,40(6): 670-672.

[28]	Bevers TB, Armstrong DK, Arun B, et al. Breast cancer risk reduction[J]. J Natl Compr Canc Netw, 2010, 8 (10): 1112-1146.